{
  "nctId": "NCT02396849",
  "briefTitle": "Modulation Of Airway Reactivity With Chronic Mechanical Strain",
  "officialTitle": "Modulation Of Airway Reactivity With Chronic Mechanical Strain",
  "protocolDocument": {
    "nctId": "NCT02396849",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2016-03-17",
    "uploadDate": "2020-12-22T15:30",
    "size": 682970,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02396849/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "SINGLE",
  "enrollmentInfo": {
    "enrollmentCount": 84,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2015-01",
    "completionDate": "2020-01-09",
    "primaryCompletionDate": "2020-01-09",
    "firstSubmitDate": "2015-03-18",
    "firstPostDate": "2015-03-24"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Children 8-17 yrs olds with severe asthma (N=120) will be recruited from the Pediatric High Risk Asthma Clinic and Pulmonary Clinics at Riley Hospital for Children at Indiana University Health.\n* Severe asthma will be defined by the need for medication therapies following steps 4-6 according to the National Institutes of Health's Asthma Care Quick Reference, September 2012 or high dose of inhaled corticosteroids\n* On a stable regimen of asthma medications for at least 8 weeks prior to enrollment without systemic corticosteroids for ≥ 4 weeks\n\nExclusion Criteria:\n\n* Obese (\\>95% predicted BMI)\n* Congenital heart disease or chronic lung disease\n* History of pneumothorax\n* Inability to perform pulmonary function testing\n* Oxygen saturation \\<93%\n* forced expiratory volume at one second (FEV1) \\<70% predicted\n* Provocative concentration causing a 20% drop in FEV1 from baseline (PC20) ≥16 mg/ml of methacholine.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "8 Years",
    "maximumAge": "17 Years",
    "stdAges": [
      "CHILD"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Change in Airway Reactivity From Baseline (Visit 1) and 4 Weeks (Visit 2)",
        "description": "The change in airway reactivity measured prior to and after 4 weeks of either CPAP or SHAM treatment. Methacholine bronchial challenge was performed using the 5-breath protocol (DeVilbiss646 with KoKo dosimeter: 9 μL/breath) with quadrupling concentrations starting with 0.0625 mg/mL and continuing until FEV1 decreased by 20% (PC20) or Methacholine concentration of 16 mg/mL was inhaled.",
        "timeFrame": "baseline (visit 1) and 4 weeks (visit 2)"
      }
    ],
    "secondary": [
      {
        "measure": "Change in Airway Inflammation From Baseline (Visit 1) and 4 Weeks (Visit 2)",
        "description": "Airway Inflammation assessed as the change in the percentage eosinophils in the induced sputum measured prior to and after 4 weeks of Continuous Positive Airway Pressure (CPAP) or sham CPAP treatment.",
        "timeFrame": "baseline (visit 1) and 4 weeks (visit 2)"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 1,
      "otherCount": 0,
      "totalCount": 2
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 44,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:29:24.521Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}